153 related articles for article (PubMed ID: 11017118)
1. Pediatric study of medicines becomes mandatory.
Bonetta L
Nat Med; 2000 Oct; 6(10):1069. PubMed ID: 11017118
[No Abstract] [Full Text] [Related]
2. FDA notifications. Pediatric formulation of lamivudine approved.
AIDS Alert; 2008 Mar; 23(3):32-3. PubMed ID: 18663776
[No Abstract] [Full Text] [Related]
3. FDA notifications. FDA approves pediatric efficacy supplement for didanosine capsules.
AIDS Alert; 2008 Nov; 23(11):129. PubMed ID: 19043871
[No Abstract] [Full Text] [Related]
4. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
5. FDA notifications. FDA approved pediatric efficacy supplement for Retrovir syrup.
AIDS Alert; 2008 Nov; 23(11):128. PubMed ID: 19043870
[No Abstract] [Full Text] [Related]
6. Pediatric drug trials. Challenge to FDA's authority may end up giving it more.
Marshall E
Science; 2002 May; 296(5569):820-1. PubMed ID: 11988539
[No Abstract] [Full Text] [Related]
7. FDA notifications. Efavirenz 100 mg scored tablets approved for pediatric treatment.
AIDS Alert; 2009 Mar; 24(3):34-5. PubMed ID: 19445002
[No Abstract] [Full Text] [Related]
8. Drug development process for a product with a primary pediatric indication.
Allen AJ; Michelson D
J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
[TBL] [Abstract][Full Text] [Related]
9. EU law mandates drug testing in children.
Sinha G
J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
[No Abstract] [Full Text] [Related]
10. Pediatric drug studies. Protecting pint-sized patients.
Nordenberg T
FDA Consum; 1999; 33(3):23-8. PubMed ID: 10443186
[No Abstract] [Full Text] [Related]
11. Is the "therapeutic orphan" about to be adopted?
Coté CJ; Kauffman RE; Troendle GJ; Lambert GH
Pediatrics; 1996 Jul; 98(1):118-23. PubMed ID: 8668382
[No Abstract] [Full Text] [Related]
12. Current challenges in pediatric drug development.
Adamson PC
Clin Adv Hematol Oncol; 2008 Dec; 6(12):883-4. PubMed ID: 19209138
[No Abstract] [Full Text] [Related]
13. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
14. FDA notifications. Generic lamivudine tentatively approved.
AIDS Alert; 2005 Dec; 20(12):142. PubMed ID: 16400721
[No Abstract] [Full Text] [Related]
15. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
Novak E; Allen PJ
Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005
[TBL] [Abstract][Full Text] [Related]
16. The march toward rational therapeutics in children.
Gorman RL
Pediatr Infect Dis J; 2003 Dec; 22(12):1119-23. PubMed ID: 14688584
[TBL] [Abstract][Full Text] [Related]
17. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
Karst KR
Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
[No Abstract] [Full Text] [Related]
18. The United States Food and Drug Administration and the end of antibiotics.
Shlaes DM; Moellering RC
Clin Infect Dis; 2002 Feb; 34(3):420-2. PubMed ID: 11774094
[No Abstract] [Full Text] [Related]
19. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
20. Video: pediatric medicines--prescribing drugs "off-label".
Frederick R
Science; 2008 Oct; 322(5899):209. PubMed ID: 18845741
[No Abstract] [Full Text] [Related]
[Next] [New Search]
